Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.1205759 on May 9, 2006

Published online before print May 9, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1205759v1
80/1/196    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lennartsson, A.
Right arrow Articles by Gullberg, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennartsson, A.
Right arrow Articles by Gullberg, U.
(Journal of Leukocyte Biology. 2006;80:196-203.)
© 2006 by Society for Leukocyte Biology

All-trans retinoic acid-induced expression of bactericidal/permeability-increasing protein (BPI) in human myeloid cells correlates to binding of C/EBPß and C/EBP{epsilon} to the BPI promoter

Andreas Lennartsson*, Karina Vidovic*, Malene Bjerregaard Pass{dagger}, Jack B. Cowland{dagger} and Urban Gullberg*,1

* Division of Hematology and Transfusion Medicine, Lund University, Sweden; and
{dagger} Granulocyte Research Laboratory, Rigshospitalet, Copenhagen, Denmark

1 Correspondence: Department of Hematology, BMC, C14, S-221 84 Lund, Sweden. E-mail: urban.gullberg{at}med.lu.se

Bactericidal/permeability-increasing protein (BPI) neutralizes the proinflammatory effects of lipopolysaccharide and is of potential clinical use in the treatment of fulminant Gram-negative infections. BPI is a cationic protein with antibacterial activity stored in azurophil (primary) granules of neutrophil granulocytes. However, the absence of BPI in patients with specific granule deficiency indicates a transcriptional control of BPI, which is distinct from that of other azurophil granule proteins. Accordingly, we demonstrate in vivo that the BPI mRNA level peaks, together with mRNA for specific granule proteins, during the myelocytic and metamyelocytic stage of granulocytic maturation. The human promyelocytic cell line NB4 expresses several azurophil granule proteins, but expression of BPI is undetectable. We show that treatment of NB4 cells with all-trans retinoic acid (ATRA) induces BPI expression at mRNA and at protein level. The induction is dependent on de novo protein synthesis, as judged by sensitivity to cycloheximide. Previous investigations have indicated a potential role of CCAAT/enhancer-binding protein (C/EBP) transcription factors in the regulation of BPI expression. Here, we show that induction of NB4 cells with ATRA correlates to direct binding of C/EBPß and C/EBP{epsilon} to the proximal BPI promoter, as determined by electrophoretic mobility shift analysis and chromatin immunoprecipitation. The dependency on C/EBPß and C/EBP{epsilon} provides an explanation for delayed BPI mRNA expression, as compared with mRNA of other azurophil granule proteins.

Key Words: transcriptional regulation • granulocyte • azurophil granule protein • innate immunity






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Leukocyte Biology.